|  | Non-White (N=2254) | White (N=5722) | Overall (N=7976) |
| --- | --- | --- | --- |
| **In-hospital Mortality** |  |  |  |
| Died | 687 (30.5%) | 1,445 (25.3%) | 2,132 (26.7%) |
| Survived | 1,565 (69.4%) | 4,274 (74.7%) | 5,839 (73.2%) |
| **Mechanic Ventilation** |  |  |  |
| Did not receive | 1,261 (55.9%) | 3,501 (61.2%) | 4,762 (59.7%) |
| Received | 993 (44.1%) | 2,221 (38.8%) | 3,214 (40.3%) |
| **Renal Replacement Therapy** |  |  |  |
| Did not receive | 1,942 (86.2%) | 5,204 (90.9%) | 7,146 (89.6%) |
| Received | 312 (13.8%) | 518 (9.1%) | 830 (10.4%) |
| **Vasopressor(s)** |  |  |  |
| Did not receive | 1,257 (55.8%) | 3,107 (54.3%) | 4,364 (54.7%) |
| Received | 997 (44.2%) | 2,615 (45.7%) | 3,612 (45.3%) |
| **Age by group (years)** |  |  |  |
| 18 - 44 | 159 (7.1%) | 242 (4.2%) | 401 (5.0%) |
| 45 - 64 | 794 (35.2%) | 1,852 (32.4%) | 2,646 (33.2%) |
| 65 - 74 | 607 (26.9%) | 1,677 (29.3%) | 2,284 (28.6%) |
| 75 - 84 | 466 (20.7%) | 1,287 (22.5%) | 1,753 (22.0%) |
| 85 and higher | 228 (10.1%) | 664 (11.6%) | 892 (11.2%) |
| **Age overall (years)** |  |  |  |
| Mean (SD) | 66.5 (14.3) | 68.6 (13.0) | 68.0 (13.4) |
| Median [Min, Max] | 67.0 [19.0, 100] | 69.0 [20.0, 100] | 68.0 [19.0, 100] |
| **Sex** |  |  |  |
| Female | 957 (42.5%) | 2,109 (36.9%) | 3,066 (38.4%) |
| Male | 1,297 (57.5%) | 3,613 (63.1%) | 4,910 (61.6%) |

|  |  |  |  |
| --- | --- | --- | --- |
| **SOFA** |  |  |  |
| 0 - 5 | 933 (41.4%) | 2,802 (49.0%) | 3,735 (46.8%) |
| 6 - 10 | 902 (40.0%) | 2,105 (36.8%) | 3,007 (37.7%) |
| 11 - 15 | 341 (15.1%) | 693 (12.1%) | 1,034 (13.0%) |
| 16 and above | 78 (3.5%) | 122 (2.1%) | 200 (2.5%) |
| **SOFA overall** |  |  |  |
| Mean (SD) | 7.05 (3.86) | 6.38 (3.60) | 6.57 (3.69) |
| Median [Min, Max] | 6.00 [0, 22.0] | 6.00 [0, 21.0] | 6.00 [0, 22.0] |
| **Charlson index** |  |  |  |
| 0 - 5 | 431 (19.1%) | 1,247 (21.8%) | 1,678 (21.0%) |
| 6 - 10 | 1,360 (60.3%) | 3,377 (59.0%) | 4,737 (59.4%) |
| 11 - 15 | 447 (19.8%) | 1,047 (18.3%) | 1,494 (18.7%) |
| 16 and above | 16 (0.7%) | 51 (0.9%) | 67 (0.8%) |
| **Charlson index overall** |  |  |  |
| Mean (SD) | 8.07 (3.00) | 7.94 (3.01) | 7.98 (3.01) |
| Median [Min, Max] | 8.00 [0, 19.0] | 8.00 [0, 20.0] | 8.00 [0, 20.0] |
| **Length of stay (days)** |  |  |  |
| Mean (SD) | 15.4 (17.3) | 15.2 (18.3) | 15.3 (18.0) |
| Median [Min, Max] | 9.83 [0, 164] | 9.59 [0, 221] | 9.66 [0, 221] |

|  |  |  |  |
| --- | --- | --- | --- |
| **Active Cancer by Type** |  |  |  |
| Breast | 43 (1.9%) | 71 (1.2%) | 114 (1.4%) |
| Prostate | 98 (4.3%) | 180 (3.1%) | 278 (3.5%) |
| Lung (including bronchus) | 114 (5.1%) | 294 (5.1%) | 408 (5.1%) |
| Colon and Rectal (combined) | 27 (1.2%) | 14 (0.2%) | 41 (0.5%) |
| Melanoma | 0 (0%) | 18 (0.3%) | 18 (0.2%) |
| Bladder | 21 (0.9%) | 120 (2.1%) | 141 (1.8%) |
| Endometrial | 0 (0%) | 2 (0.0%) | 2 (0.0%) |
| Leukemia | 3 (0.1%) | 6 (0.1%) | 9 (0.1%) |
| Pancreatic | 29 (1.3%) | 78 (1.4%) | 107 (1.3%) |
| Thyroid | 12 (0.5%) | 15 (0.3%) | 27 (0.3%) |
| Liver and intrahepatic BD | 163 (7.2%) | 312 (5.5%) | 475 (6.0%) |
| Metastasized | 4 (0.2%) | 12 (0.2%) | 16 (0.2%) |
| Other | 1,740 (77.2%) | 4,600 (80.4%) | 6,340 (79.5%) |